8 July 2024 - Adicet Bio today announced the US FDA has granted fast track designation to ADI-270 for the potential treatment of patients with metastatic/advanced clear cell renal cell carcinoma who have been treated with an immune checkpoint inhibitor and a vascular endothelial growth factor inhibitor.

ADI-270 is an armoured allogeneic “off-the-shelf” gamma delta CAR-T cell therapy candidate targeting CD70 positive cancers.

Read Adicet Bio press release